REG - hVIVO plc - Rule 2.9 Announcement

hVIVOAnnouncement

27/12/2019 08:05

RNS Number : 5284X
hVIVO plc
27 December 2019
 


hVIVO plc
 
("hVIVO or the "Company")
 
Rule 2.9 Announcement
 
In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,421,879 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in hVIVO is 83,421,879. The International Securities Identification Number ("ISIN") for hVIVO's ordinary shares is GB00B6ZM0X53.
 
For further information please contact:
 
hVIVO plc                                                                                                     +44 (0)20 7756 1300
Anesh Patel, Interim Finance Director and Company Secretary
Fleur Wood, EVP, Investor Relations & Communications
 
Numis Securities Limited (Nominated Adviser)                                      +44 (0)20 7260 1000
Freddie Barnfield / Huw Jeremy
 
FTI Consulting (Financial PR)                                                                   +44 (0)20 3727 1000
Simon Conway / Victoria Foster Mitchell
 
 
Notes to Editors:
hVIVO plc is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RTTTLBJTMBTBBIL